TrialCombination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Trial details
- Registry ID
- NCT05054725
- Phase
- Phase 2
RVMD
Revolution Medicines, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
6Trials in this database
7Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourcePhase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Trial details
- Registry ID
- NCT06625320
- Phase
- Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Trial details
- Registry ID
- NCT06881784
- Phase
- Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Trial details
- Registry ID
- NCT07252232
- Phase
- Phase 3
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Trial details
- Registry ID
- NCT07491445
- Phase
- Phase 3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Trial details
- Registry ID
- NCT07621718
- Phase
- Phase 3
Latest recorded trial changes
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784 · Revolution Medicines, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Progression free survival (PFS) per Investigator in the RAS G12X-C population (i.e RAS G12X excluding G12C)
Measure: Overall survival (OS) in the RAS G12X-C population
+ After
Measure: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C) Measure: Overall survival (OS) in the RAS G12X-C population
Planned enrollment increased by 170 participants
− Before
420 participants (planned)
+ After
590 participants (planned)
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06625320 · Revolution Medicines, Inc.
Actual enrollment decreased by 1 participants
− Before
501 participants (actual)
+ After
500 participants (actual)
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06625320 · Revolution Medicines, Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
460 participants (planned)
+ After
501 participants (actual)
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784 · Revolution Medicines, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Progression free survival (PFS) per Investigator in the RAS G12X-C population Measure: Overall survival (OS) in the RAS G12X-C population
+ After
Measure: Progression free survival (PFS) per Investigator in the RAS G12X-C population (i.e RAS G12X excluding G12C) Measure: Overall survival (OS) in the RAS G12X-C population